for reducing thrombotic risk and fatigue in jSLE patients. Further studies are needed to address this issue.

**P4** ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

1Mikel Jordhani, 1Dorina Ruci, 1Ioana Seiti. 2Dept. Internal Medicine, Rheumatology Clinic, UHC Mother Teresa, Tirana; 3Dept. Internal Medicine, Rheumatology Clinic, UHC Mother Teresa, Tirana; 4Dept. Cardiovascular Diseases, Cardiovascular Reanimation Clinic, UHC Mother Teresa, Tirana, Albania

**Background** Antiphospholipid Syndrome (APS) is a known cause of thrombotic disorders, including Acute Myocardial Infarction (AMI). Although its incidence in APS patients is not known, it may be an important factor in precipitating infarction, especially in younger adults.

**Methods** This is a case-control study consisting in 73 patients with Acute Myocardial Infarction, hospitalized at Cardiovascular Reanimation Clinic from 10 December 2015- 10 October 2019. All patients included in the study were from 23 to 50 years old. In the case-group were included 24 patients with Antiphospholipid Syndrome and Acute Myocardial Infarction, and 49 patients were included in the control group, which consisted only in patients with AMI, with no presence of APS. In every patient were gathered data such as complete blood count + ESR, Antinuclear Antibodies (ANA), Anti-cardiolipin antibodies (ACA), C3 and C4 complement fraction, Anti-ds-DNA, CRP and Ejection Fraction (EF) in echocardiography. Female patients were asked about their abortion history. As recommended in the guidelines, in positive results for APS, ACA levels were repeated after 12 weeks in order to establish diagnosis. All data were gathered and statistically analyzed using Excel 2010 and IBM SPSS.

**Results** After comparing all gathered data, it was found that the patients with APS and AMI had a more significant ten-

10.1136/lupus-2020-eurolupus.53

**Conclusion** From our study it was found that APS is not rare in young adults with AMI. It should be always suspected in young patients with no cardiovascular risk factors and there may be a characteristic clinical and laboratory picture in patients with AMI, which may suggest the APS diagnosis.

**Acknowledgements** This work was supported by the Arthritis Research and Collaboration Hub (ARCH) Foundation.

**P6** RITUXIMAB EFFICACY IN CAPS

Olena Yakymenko, Viktoria Vasyiets, Viktor Klochko, Vladimir Savitskiy, Natalya TkHonchuk, Rheumatological Dept., Multifield Medical Center of Odessa national medical university, Odesa, Ukraine

**Background** Catastrophic antiphospholipid syndrome (CAPS) - thrombotic microangiopathy, characterized by involvement of systems and organs with formation of their insufficiency. Therapy of glucocorticoids and immunosuppressants with plasmapheresis and intravenous immunoglobulin demonstrates lack of effectivity. Currently, there are reports of rituximab effectiveness in CAPS and APS, but they are not numerous, especially CAPS.

**Methods** Assessment of the rituximab effectiveness in patients with resistant CAPS. We present the treatment results of two patients with CAPS, who were treated in our clinic.

**Results** Patient V, 21, was admitted in the early postpartum period. Diagnosis: Systemic lupus erythematosus, positivity for ANA: ds-DNA, Sm. Secondary antiphospholipid syndrome (positivity for β2-glycoprotein-1, cardiolipin, lupus anticogul-lant), catastrophic APS with multioragan failure: epilepsy, sopor, psychosis; acute renal injury, signs of acute respiratory distress syndrome and hypocoagulation. SLEDAI score was 56 points, GAPSS ~ 17 points. Pulse therapy with methylprednisolone, cyclophosphamide, plasmapheresis and intravenous immunoglobulin wasn't effective enough. Rituximab course 375 mg/m2 1 time per week for 4 weeks was administered. Manifestations...
of CAPS in multiorgan failure form regressed 14 days after the first administration, SLEDAI score decreased to 32 points, GAPSS to 4 points. After 4 weeks complete B-cell depletion was achieved. A month after the course of rituximab she achieved remission, which lasts 4 years already. ANA and antiphospholipid antibodies weren’t detected.

Patient E., 20, with primary APS, cardiolipin positivity, β2-glycoprotein-1 and lupus anticoagulant, thrombocytopenia, livedo reticularis; CAPS-like thrombotic microangiopathy type with damage to cerebral vessels, lung vessels, recurrent pulmonary embolism for six months, deep leg vein thrombosis. GAPSS activity before treatment was 17 points. Pulse therapy wasn’t performed. Therapy rituximab 375 mg/m² 1 time per week, 4 weeks was administered. Multiple organ failure also regressed 10–14 days after 1 administration of rituximab. GAPSS score decreased to 10 points. Incomplete B-cell depletion was achieved.

Conclusion Thus, rituximab demonstrated high effectiveness in CAPS in both cases. Rituximab allowed to reach multiple organ failure regression and a persistent effect was achieved.

**REFERENCES**


**Background** Catastrophic antiphospholipid syndrome (CAPS) is the most severe complication of antiphospholipid syndrome (APS). Vitamin K antagonists (VKAs) are the reference treatment for preventing relapsing thrombotic complications in patients with APS, but direct oral anticoagulants (DOACs), such as rivaroxaban, are nonetheless sometimes used in patients with antiphospholipid antibody profiles or APS. Recent studies showed that DOACs were associated with more arterial thromboses among patients with APS. The potential role of DOACs as a trigger factor of CAPS is not known.

**Methods** We describe two patients who developed a CAPS in the week following the institution of rivaroxaban.

**Results** We report the onset of definite CAPS in the week following introduction of rivaroxaban treatment in two patients, one with APS and the other with antiphospholipid laboratory findings only. Both were triple positive for antiphospholipid antibodies. The affected organs were the heart, kidneys, skin, and liver for Patient 1, and the heart, kidneys, skin, adrenal gland, and central nervous system for Patient 2. The causative role of rivaroxaban is highly probable given that (1) CAPS occurred rapidly after this treatment was started, (2) an alternative trigger factor was found in Patient 1 only (a colonoscopy), and (3) Patient 1 had been clinically stable for 18 years with VKA as anticoagulant treatment, while Patient 2 did not have APS and had no symptoms for 4 months (rivaroxaban had been introduced because at a scheduled visit, she reported neurological symptoms that occurred four months before and were retrospectively compatible with a brain transient ischemic accident). One similar case was reported in 2017, also following the introduction of rivaroxaban, in a patient with triple positive venous thrombotic APS who was stable for years on warfarin and who developed definite CAPS (involvement of the myocardium and adrenal glands as well as a pulmonary embolism) in the week after rivaroxaban 20 mg daily replaced warfarin to meet the patient’s desire for a less burdensome treatment. Finally, in the randomized study published by Ordi-Ros et al, one of the patients treated with rivaroxaban developed a CAPS.

**Conclusions** These two cases, as well as two previous reported cases, underline the importance of avoiding DOACs in patients with APS, especially those triple positive for antiphospholipid antibodies. VKAs must remain the reference anticoagulation treatment in this setting.

**P8 REFRACTORY THROMBOCYTOPENIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SECONDARY ANTIPHOSPHOLIPID SYNDROME**

1Rita Torres, 1Maria João Gonçalves, 1,2Nuno Gonçalves, 1,2Santiago Marica, 1,2Agna Neta, 1,2José Marana, 1Manuela Costa, 1,2Fernando M F displante-Santos, 1,2Jaime C Branco. 1Rheumatology Dept., Centro Hospitalar Lisboa Ocidental, Hospital de Ega Moniz, Lisboa; 2NOVA Medical School, Universidade NOVA de Lisboa, Lisboa, Portugal

**Background** Thrombocytopenia is a frequent hematological manifestation in patients with systemic lupus erythematosus (SLE), usually treated with glucocorticoids, immunosuppressants (such as azathioprine and cyclophosphamide), intravenous immunoglobulin (IVIG) or splenectomy.

**Case report** A 44-year-old woman diagnosed with SLE and secondary antiphospholipid antibody syndrome was admitted in our hospital, in July 2018, presenting severe renal and hematological involvement. She underwent treatment with methyldenisolone, followed by prednisolone, and mycophenolate mofetil, with no response. In August 2018, the patient started haemodialysis, human immunoglobulin (transient response) and plasmapheresis due to evidence of secondary thrombotic microangiopathy. The refractory severe thrombocytopenia and lupus nephritis, justify two cycles of rituximab - platelet count rising lasted for five months. Seven months later, the patient presented pancytopenia and due to high hemorrhagic risk, there was a switch from warfarin to LMWH (prophylactic dosing). One month later, anti-coagulation was suspended due to spontaneous intracranial bleeding. In August 2019, the patient had an ischemic stroke of the right occipital lobe, secondary to APS, under prednisolone and hydroxychloroquine, and with platelet count of 24,000/μL. Because of the bleeding risk, no anti-aggregation was instituted, and she started tacrolimus - the initial good response disappeared two weeks later. After consulting a rheumatology board, tacrolimus was kept and rituximab repeated, regardless of the hypogammaglobulinemia and no lymphocytes CD19+ count.

**Conclusion** We experienced a severe case of secondary thrombocytopenia, that was refractory to multiple therapeutic agents. A reasonable response was obtained under rituximab. Tacrolimus is kept due to the reported cases of late effect. Ischaemic stroke is a challenging condition in patients thrombocytopenic and further clinical guidance is warranted.